[go: up one dir, main page]

CL2018003281A1 - Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds). - Google Patents

Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds).

Info

Publication number
CL2018003281A1
CL2018003281A1 CL2018003281A CL2018003281A CL2018003281A1 CL 2018003281 A1 CL2018003281 A1 CL 2018003281A1 CL 2018003281 A CL2018003281 A CL 2018003281A CL 2018003281 A CL2018003281 A CL 2018003281A CL 2018003281 A1 CL2018003281 A1 CL 2018003281A1
Authority
CL
Chile
Prior art keywords
apds
treatment
trifluoroethyl
specific
kinase delta
Prior art date
Application number
CL2018003281A
Other languages
English (en)
Inventor
Rodger Anthony Allen
Martin John Armstrong
Marina Cavazzana
Sven Kracker
Duncan Philip Mchale
Andrew Charles Payne
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2018003281A1 publication Critical patent/CL2018003281A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

N-{(R)-1-[8-CLORO-2-(1-OXIPIRIDIN-3-IL)-QUINOLIN-3-IL]-2,2,2-TRIFLUOROETIL}-PIRIDO[3,2-D]. LA PIRIMIDIN-4-ILAMINA ES EFECTIVA EN EL TRATAMIENTO Y/O PREVENCIÓN DEL SÍNDROME DE FOSFOINOSITIDA 3-CINASA DELTA ACTIVADA (APDS).
CL2018003281A 2016-05-19 2018-11-19 Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds). CL2018003281A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1608797.5A GB201608797D0 (en) 2016-05-19 2016-05-19 Therapeutic use

Publications (1)

Publication Number Publication Date
CL2018003281A1 true CL2018003281A1 (es) 2019-01-25

Family

ID=56369612

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003281A CL2018003281A1 (es) 2016-05-19 2018-11-19 Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds).

Country Status (18)

Country Link
US (1) US20190209567A1 (es)
EP (1) EP3458065A1 (es)
JP (1) JP2019516703A (es)
KR (1) KR20190009790A (es)
CN (1) CN109152783A (es)
AR (1) AR108500A1 (es)
AU (1) AU2017267172A1 (es)
BR (1) BR112018072450A2 (es)
CA (1) CA3023974A1 (es)
CL (1) CL2018003281A1 (es)
CO (1) CO2018013559A2 (es)
EA (1) EA201892638A1 (es)
GB (1) GB201608797D0 (es)
IL (1) IL262943A (es)
MX (1) MX2018013770A (es)
RU (1) RU2018144187A (es)
SG (1) SG11201809396SA (es)
WO (1) WO2017198590A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
US10150756B2 (en) 2014-01-31 2018-12-11 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
CA2944611A1 (en) * 2014-05-27 2015-12-03 Almirall, S.A. Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile

Also Published As

Publication number Publication date
CO2018013559A2 (es) 2019-02-28
AR108500A1 (es) 2018-08-29
GB201608797D0 (en) 2016-07-06
JP2019516703A (ja) 2019-06-20
SG11201809396SA (en) 2018-11-29
AU2017267172A1 (en) 2018-12-13
US20190209567A1 (en) 2019-07-11
WO2017198590A1 (en) 2017-11-23
RU2018144187A3 (es) 2020-06-19
IL262943A (en) 2018-12-31
RU2018144187A (ru) 2020-06-19
EP3458065A1 (en) 2019-03-27
CN109152783A (zh) 2019-01-04
CA3023974A1 (en) 2017-11-23
MX2018013770A (es) 2019-03-21
BR112018072450A2 (pt) 2019-02-19
KR20190009790A (ko) 2019-01-29
EA201892638A1 (ru) 2019-06-28

Similar Documents

Publication Publication Date Title
CL2018003281A1 (es) Análogo de trifluoroetil quinolina específico para usarse en el tratamiento del síndrome de fosfoinositida 3-cinasa delta activada (apds).
EP3673905A4 (en) COMPOSITION CONTAINING CANNABIDIOL AND / OR CANNABIDIVARINE AND APPLICATION OF THE COMPOSITION IN THE TREATMENT OF DYSMENORRHEA
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
EP3501527C0 (en) COMPOSITION FOR PREVENTING OR TREATING A MENTAL DISORDER, CONTAINING A VESICLE DERIVED FROM BACTERIA OF AN ELACTOBACILLUS SPECIES
MX2017000394A (es) Vacunas para virus influenza y usos de las mismas.
CL2015001374A1 (es) Compuestos derivados de 2-(metilamino)-n-(2-oxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3il)propanamida; composicion farmaceutica; y su uso en el tratamiento terapeutico o profilactico del cancer.
LT3442547T (lt) Lactobacillus reuteri mm4-1a, skirta naudoti autizmo spektro sutrikimų gydymui arba prevencijai
PH12017500615A1 (en) Ophthalmic composition comprising cyclosporine and trehalose
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
ZA202104891B (en) Liposomial eye drops solution and uses thereof for the treatment of dry eye syndrome
EA201792346A1 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc)
EP3185862A4 (en) PROTECTIVE METALLOTHIONEIN ANALOGUES, THEIR COMPOSITIONS AND THEIR USE IN THE TREATMENT OF PATHOGENIC DISEASES
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.
MX2016007803A (es) Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso.
EP4338751C0 (en) COMBINATION OF SEPETAPROST AND NETARSUDIL FOR USE IN THE PROPHYLAXIS OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION
EP3689345A4 (en) Composition for prevention, alleviation, and/or treatment of heat stroke
WO2014117010A3 (en) Composition for ophthalmic administration
CY1122572T1 (el) Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren
WO2017129577A8 (en) Ophthalmic gabapentin for the treatment of corneal ulcers
LT3758799T (lt) Kompozicija, skirta odos pažaidų, sukeltų apšvietimo, profilaktikai ir gydymui
HUE057646T2 (hu) Tirotricin testszag kezelésében és/vagy megelõzésében történõ alkalmazásra, és erre szolgáló készítmények
EA201992210A1 (ru) Предотвращение и/или лечение воспалительного заболевания кожи
MX2019000006A (es) Composiciones para el tratamiento de estrias y ulceras de origen isquemico.
WO2015162552A3 (en) Composition for topic use
IT201700109607A1 (it) Composizione per l'uso nella prevenzione e/o nel trattamento del glaucoma.